Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10659784 | 0.94 | DNM1 (0.41) | CYP19A1DNM1MEN1KMT2AALDH1A1 | |
| SCHEMBL8222748 | 0.92 | CYP19A1 (0.38) | CYP19A1DNM1MEN1KMT2AALDH1A1 | |
| SCHEMBL9895106 | 0.85 | CYP19A1 (0.36) | CYP19A1HSD17B10KDM4EPKM | |
| SCHEMBL29775979 | 0.80 | HSD17B10 (0.37) | CYP19A1HSD17B10KDM4EPKM | |
| SCHEMBL10664843 | 0.79 | ALDH1A1 (0.40) | CYP19A1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL10659897 | 0.79 | CYP19A1 (0.35) | CYP19A1MEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL10665792 | 0.78 | SMN1; SMN2 (0.42) | CYP19A1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL1359080 | 0.77 | GAA (0.39) | CYP19A1HSD17B10KDM4EPKM | |
| SCHEMBL6331007 | 0.77 | TDP1 (0.40) | CYP19A1HSD17B10 | |
| SCHEMBL23354908 | 0.75 | MMP2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0088977-B1 | ELECTRON BEAM SENSITIVE RESIST | GAF CORPORATION (US) | 1988-06-01 | — | — | EP | claimed |
| US-4448875-A | HALF-ESTER OR -AMIDE OF ALKYL VINYL ETHER-MALEIC ANHYDRIDE COPOLYMER | GAF CORPORATION (US) | 1984-05-15 | — | — | US | claimed |
| US-9334236-B2 | Lactam-based compounds with a urethane or urea functional group, and uses thereof | ISP INVESTMENTS INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20120149861-A1 | LACTAM-BASED COMPOUNDS WITH A URETHANE OR UREA FUNCTIONAL GROUP, AND USES THEREOF | ISP INVESTMENTS LLC | 2012-06-14 | — | — | US | disclosed |
| WO-2011022457-A1 | LACTAM-BASED COMPOUNDS WITH A URETHANE OR UREA FUNCTIONAL GROUP, AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| EP-0541536-A1 | ALKYL VINYL ETHER POLYMERS CONTAINING A LACTAM FUNCTIONALITY | ISP INVESTMENTS INC. (US) | 1993-05-19 | — | — | EP | disclosed |
| EP-0541536-A4 | ALKYL VINYL ETHER POLYMERS CONTAINING A LACTAM FUNCTIONALITY. | ISP INVESTMENTS INC (US) | 1992-10-03 | — | — | EP | disclosed |
| EP-0088977-B1 | ELECTRON BEAM SENSITIVE RESIST | GAF CORPORATION (US) | 1988-06-01 | — | — | EP | disclosed |
| US-4448875-A | HALF-ESTER OR -AMIDE OF ALKYL VINYL ETHER-MALEIC ANHYDRIDE COPOLYMER | GAF CORPORATION (US) | 1984-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149861-A1 | LACTAM-BASED COMPOUNDS WITH A URETHANE OR UREA FUNCTIONAL GROUP, AND USES THEREOF | CUTA, PUF60, PAM | CYP19A1 970/4885DNM1 3095/4885MEN1 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.